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Abstract. Motivation: Despite being often perceived as the main contributors
to cell fate and physiology, genes alone cannot predict cellular phenotype. During
the process of gene expression, 95% of human genes can code for multiple pro-
teins due to alternative splicing. While most splice variants of a gene carry the
same function, variants within some key genes can have remarkably different roles.
To bridge the gap between genotype and phenotype, condition- and tissue-specific
models of metabolism have been constructed. However, current metabolic models
only include information at the gene level. Consequently, as recently acknowledged
by the scientific community, common situations where changes in splice-isoform
expression levels alter the metabolic outcome cannot be modeled.
Results: We here propose GEMsplice, the first method for the incorporation of
splice-isoform expression data into genome-scale metabolic models. Using GEM-
splice, we make full use of RNA-Seq quantitative expression profiles to predict,
for the first time, the effects of splice isoform-level changes in the metabolism
of 1455 patients with 31 different breast cancer types. We validate GEMsplice
by generating cancer-versus-normal predictions on metabolic pathways, and by
comparing with gene-level approaches and available literature on pathways af-
fected by breast cancer. GEMsplice is freely available for academic use at https:
//github.com/GEMsplice/GEMsplice_code. Compared to state-of-the-art meth-
ods, we anticipate that GEMsplice will enable for the first time computational
analyses at transcript level with splice-isoform resolution.
1 Introduction
The increasing availability of multi-omic datasets has rapidly moved the focus of
many research efforts from data collection to finding effective methods for data
interpretation and analysis. In terms of biomedical results, this step is therefore
currently considered more limiting than data collection itself [1].
Genes and their expression have been the subject of the vast majority of research
studies in computational biology and bioinformatics. However, it is the interaction
of genes, proteins, reactions, and metabolites (different omics) that shapes the
behavior of a cell. When analyzing biological models, the classical pathway-based
perspective has been replaced, in the last 20 years, by a network-based approach,
therefore bypassing parametrization and need for kinetic data, and leading to the
generation of genome-scale metabolic models. These models include thousands of
biochemical reactions, often the full set of reactions known for a given organism,
allowing for prediction of cell phenotype. In this regard, metabolism is the only
biological system that can be fully modeled at genome-scale, and also the closest
to the phenotype.
Metabolism is now considered as a driver, rather than a marker, of cancer onset
and proliferation. In breast cancer, metabolic heterogeneity is one of the causes of
poor clinical outcome: although being classified as a single disease, more than 20
types of breast cancer exist. A genome-scale analysis of cancer metabolism captures
many effects that could not be identified using standard data and gene expression
analysis. Furthermore, a wide set of tools for the incorporation of cancer omic data
into these models have been developed, making them suitable for integrating and
interpreting the great amount of data that is being gathered on cancer metabolic
alterations [2].
As mentioned above, reduced cost for data gathering and analysis has recently
yielded a rapid increase in the amount of available omics data. RNA-Seq is now
widely used to produce high-throughput data in more detail compared to mi-
croarrays, with a more accurate estimation of transcript levels. As a result, splice
isoform expression levels are now becoming available in cancer studies, where the
same gene can code for multiple proteins due to alternative RNA splicing before
translation. Alterations of specific splice-isoform expression in some genes can con-
stitute a biomarker for cancer metabolism. In humans, alternative splicing affects
95% of multiexon genes [3].
However, to date, functional information included in most metabolic models refers
to genes or proteins only. The idea exploited here is that splice isoform data can
be readily integrated and used in conjunction with annotated genome-scale models
in order to constrain and refine existing models. Although Recon1 [4] was the only
human metabolic model that introduced isoform-level annotations for some genes
through bibliographic research, it adopted a custom annotation for isoforms, and
therefore did not allow any mapping to known identifiers from public databases.
For these reasons, such annotations have been subsequently lost and then simply
ignored, mapping transcriptomic data with gene-level resolution only [5]. Conse-
quently, expression data at the splice-isoform level has been neglected or simply
averaged within the same gene to approximate the expression at the gene level.
Nevertheless, especially in human metabolic models, the incorporation of splice
isoforms is key to understanding complex diseases like cancer. In this regard, pyru-
vate kinase (PK) is a striking example. In fact, the switch to the second isoform of
pyruvate kinase (PKM2) is considered essential for cancer growth [6]. Conversely,
the switch from PKM2 to the main pyruvate kinase isoform (PKM1) is able to
reverse the Warburg effect and could therefore constitute a therapeutic target. In
general, these crucial isoform-level events, e.g. the switch to minor isoforms, which
get overexpressed compared to the major isoform of a gene, cannot be captured by
current metabolic models, as highlighted in a number of recent reviews [7,8,5,9].
Here we propose GEMsplice (genome-scale metabolic modeling with splice-isoform
integration), the first method for incorporating RNA-Seq data at the splice-isoform
level into a metabolic model. The GEMsplice pipeline exploits, for the first time,
the full potential of the next-generation sequencing technology in the context of
genome-scale metabolic reconstructions. As a result, it enables more accurate pre-
dictions of human metabolic behavior and cancer metabolism. We show that GEM-
splice compares favorably to existing tools for integration of transcriptomics data
at the gene level only. We also validate GEMsplice by building breast cancer-versus-
normal genome-scale models and by comparing predictions with available results
on metabolic pathways affected by breast cancer. The full GEMsplice pipeline is
illustrated in Figure 1. GEMsplice is made freely available in Matlab/Octave at
https://github.com/GEMsplice/GEMsplice_code, and is fully compatible with
the COBRA 2.0 Toolbox [10].
Beyond the Warburg effect: metabolism is a key player in cancer
formation and progression
Known molecular markers of cancer can be associated with two main classes: (i)
cell proliferation and (ii) tissue remodeling [13]. Cancer cells show higher rate of
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Fig. 1. GEMsplice incorporates RNA-Seq data into genome-scale metabolic
models at the splice-isoform level. Starting from a metabolic model of breast cancer
metabolism [11] (A), gene expression (B) and transcript level information (C) are incor-
porated into the model. As a result, for the first time, we can exploit the full potential of
next-generation sequencing in the context of genome-scale metabolic reconstructions. A
set of phenotype-specific RNA-Seq transcript expression levels in a variety of breast can-
cer types and stages from the Cancer RNA-Seq Nexus dataset [12], including data from
TCGA, GEO and SRA (D), are then mapped onto the model using constraint-based mod-
eling (E). Cancer-specific metabolic models are finally generated and investigated using
multilevel linear programming (F), leading to phenotype prediction for different types of
breast cancer (G).
proliferation than normal cells in the tissue from which they originated. The main
goal of metabolism in cancer cells is to keep cell viability and ensure new biomass
production by acquiring nutrients from an environment where nutrients are often
scarce. To this end, cancer cells exhibit a modified metabolism and an increased
need for proteins, energy, nucleotides and lipids. The two main nutrients used by
cancer cells are glucose and glutamine; both support cell growth and are used to
build carbon intermediates, which are employed in a number of processes that
build macromolecules.
The first difference between normal and cancer metabolism was observed in the
1920s by Otto Warburg [14]. Normal cells take up glucose and perform glycolysis
to obtain pyruvate, which is then transferred to the mitochondrion and used by
oxidative phosphorylation (OXPHOS) in the TCA cycle along with oxygen to effi-
ciently produce ATP. Conversely, proliferating cancer cells require higher amount
of glucose, but after obtaining pyruvate they preferentially use it to secrete lactate
in the cytoplasm. Strikingly, this rather inefficient energy production pipeline is
used also when the cell is exposed to oxygen. Preferential use of glycolysis allows
faster proliferation but maximizes the secretion of lactic acid, which damages sur-
rounding cells. This behavior, called Warburg effect or aerobic glycolysis, facilitates
proliferation and migration of cancer cells.
However, a misinterpretation of this phenomenon by Warburg himself led to the
enduring misconception that cancer cells do not use the TCA cycle to produce
ATP. Indeed, it must be noted that the vast majority of cancer cells still use the
mitochondrion and its TCA cycle to produce a fraction of the required ATP. In
fact, in contrast to quiescent cells, glycolysis does not fuel directly the TCA cy-
cle, but is essentially decoupled from it [15]. The advantage of converting excess
pyruvate into lactate instead of transferring it into the mitochondrion is that high
glycolytic activity can continue without leading to excessive flux through the elec-
tron transport system and consequent overproduction of reactive oxygen species
(ROS), or excess ATP and NADH generation, which would in turn repress glycol-
ysis. As a result of this decoupling, useful glycolytic intermediates (e.g., precursors
of serine biosynthesis) can be generated at higher rates.
Pyruvate kinase (PK), the last step in the glycolytic pathway, is responsible for
keeping the balance between the production of pyruvate for the mitochondrion
(high PK activity) and the production of glycolytic intermediates for biosynthesis
(low PK activity). This is achieved through the preferential expression of PKM1
or PKM2, two splice isoforms of PK whose activity respectively supports pyruvate
or glycolytic intermediates for biosynthetic processes. In cancer phenotypes, being
mostly controlled by the isoform PKM2, PK and its ATP product are independent
of oxygen, therefore enabling ATP generation and growth during hypoxia (unlike
mitochondrial respiration, which needs oxygen).
Glucose is not the only key nutrient for cancer cells. Proliferating cells can consume
up to ten times more glutamine than any other amino acid. Glutamine is used
as a carbon source for fatty acid synthesis, in biosynthetic pathways (especially
the biosynthesis of nucleotides), and for TCA cycle intermediates (although as
a secondary source, less than glucose). While in normal cells glucose/glutamine
intake depends mainly on extracellular stimuli, mutations undergone by cancer cells
confer the ability to proliferate with a high degree of independence, by constantly
importing amino acids and glucose from the extracellular environment [16]. Taken
together, these studies show that metabolism, once believed to be mainly a passive
indicator of the state of a cell, is now widely recognized as a key player in cancer
formation and progression.
2 Methods
Incorporating RNA-Seq data into a breast cancer model at the
splice-isoform level
To model splice-isoform data in the breast cancer metabolic model, 31 RNA-Seq
expression profiles of breast cancer were considered from Cancer RNA-Seq Nexus
[12], which provides phenotype-specific transcript expression levels in a variety
of cancer types and stages. In Cancer RNA-Seq Nexus, data were processed as
follows. For GEO/SRA samples, Bowtie [17] was used to align RNA-Seq reads to
the reference human transcriptome from GENCODE [18]; eXpress [19] was then
used to obtain FPKM isoform abundances. For TCGA samples, starting from
Level 3 RNA-Seq v2 “tau values” quantified through RSEM [20], TPM values
were obtained through multiplication by 106.
The expression values, at this point, are measured in FPKM for GEO/SRA,
and in TPM for TCGA samples. FPKMs were then converted to TPMs using
the following formula for all the expression values j in each sample i: TPMij =
106
FPKMij
λi
∑
j FPKMij
, where
∑
j FPKMij is the sum of the FPKM values of all the
transcripts in the ith sample, and λi a sample-specific scaling factor accounting for
the fact that the number of transcripts varies across the different samples, λi =
(number of transcripts in the largest sample)/(number of transcripts in sample i).
We remark that TPM (and not FPKM) expression values were used as a starting
point to generate the metabolic outcome across samples because they are propor-
tional to the abundance and independent of the mean expressed transcript length,
therefore making them more suitable to comparisons across samples [20].
Transcript annotations in Cancer RNA-Seq Nexus consist of Ensembl and UCSC
IDs. These were converted to RefSeq annotations using BioMart [21]. However,
the breast cancer model is annotated only with gene-level Entrez IDs. To expand
these and generate transcript-level IDs with splice-isoform resolution, RefSeq IDs
for 141 transcripts were retrieved from the SBML source of Recon1 using a custom
script, as they were not included in the final Matlab version of the model (see
File S1). These newly generated transcript-level RefSeq IDs and the gene-level
default Entrez IDs of the remaining genes in the model were used to associate each
transcript in the model with the corresponding expression value in the 31 RNA-Seq
cancer profiles. The profiles were finally mapped onto the breast cancer metabolic
model (see Figure 1, and the following Methods subsection for details on how the
mapping was achieved).
Phenotype predictions from RNA-Seq data
Breast cancer is a multifactorial disease and, as a result, breast cancer cells are in-
trinsically multi-target. To model this behavior and generate cancer-specific models
from Cancer RNA-Seq Nexus, an extended flux balance analysis (FBA) framework
was used, coupled with a multi-omic integration method and multi-level linear pro-
gramming. Several approaches have been proposed and reviewed for the integration
of gene expression data into FBA models [22,23]. Each reaction in a FBA model is
controlled by an associated gene set, defined through AND/OR Boolean operators
between genes. In this work, METRADE [24] was used to constrain the upper-
and lower- limits of each reaction as a function of the expression level of the gene
set controlling the reaction.
Multiple cellular targets were modeled as a trilevel linear program:
max hᵀv
such that max gᵀv
such that max fᵀv, Sv = 0,
vminϕ(Θ) ≤ v ≤ vmaxϕ(Θ),
(1)
where S is the stoichiometry matrix of the metabolic reactions in the cell, v is the
vector of reaction flux rates, while f , g, h are Boolean vectors of weights selecting
the three reactions in v whose flux rate will be considered as objective. Lower-
and upper-limits for the flux rates in v in the unconstrained model are given by
the vectors vmin and vmax. The vector Θ represents the gene set expression of
the reactions associated with the fluxes in v. The expression level Θ of a gene set
is defined from the expression levels θ(g) of its genes. According to the type of
gene set, we define Θ(g) = θ(g) for single genes, Θ(g1∧ g2) = min{θ(g1), θ(g2)} for
enzymatic complexes, and Θ(g1∨g2) = max{θ(g1), θ(g2)} for isozymes. These rules
were applied recursively in case of nested gene sets. To enable transcript-specificity,
METRADE was also applied at the splice-isoform level, with annotations retrieved
as above. The function ϕ maps the expression level of each gene set to a coefficient
for the lower- and upper-limits of the corresponding reaction, and is defined as
ϕ(Θ) = [1+ γ |log(Θ)|]sgn(Θ−1) . (2)
Note that the vector notation was adopted, with the convention 00 = 1 when some
element of Θ is 1. The sign operator returns a vector of ±1 (signs of Θ − 1). γ
models the reliability of the gene set expression level as an indicator of the rate of
production of the associated enzyme.
One may argue that gene expression data is not a good proxy for protein abun-
dance and ultimately for flux rates. However, gene expression data is certainly the
omic data with better quality and coverage (almost always genome-scale). Further-
more, in mammals, mRNA levels can be considered the main contributors to the
overall protein expression level [25,26]. Positive correlation between mRNA and
protein levels was also recently found in most normal and cancer cell lines [27]. We
remark that, although GEMsplice natively handles absolute expression values, it
can also handle fold-change values directly, by replacing the logarithmic map (2)
with ϕ(Θ) = Θγ (see README file in the source code). Furthermore, our method
is general and not dependent on a particular proxy. For instance, one may use
protein abundances within the same approach proposed here. All simulations were
carried out in Matlab R2016b and Octave 4.0.3, with the GLPK solver.
Modeling cancer biomarkers in multi-level linear programming.
The three objectives of the linear program in Equation (1) are chosen to model
known mechanisms and key players in cancer metabolism. Here we consider: (i) the
biomass (growth rate) reaction, (ii) pyruvate kinase (PK) and (iii) lactate dehydro-
genase (LDH). (Note however that this is fully customizable in GEMsplice.) In our
pipeline, we minimize the maximum allowed flux rate of PK as the second level of
the trilevel linear program, selected through the vector g. As a third (outer) level
of our linear program, selected by the vector h, we model the Warburg effect by
minimizing the flux through LDH. In fact, a negative flux rate of this reversible re-
action models the production of lactate from pyruvate. The first level (inner level),
governed by the vector f , is assigned to represent the maximization of the flux
through the biomass reaction, modeling the observation that cancer cells grow and
divide faster than normal cells in order to achieve their main goal, proliferation.
3 Results
GEMsplice maps RNA-Seq expression levels and splice isoforms
onto a genome-scale model of breast cancer
GEMsplice maps RNA-Seq expression profiles to the metabolic model of breast
cancer, using for the first time splice isoform annotations. A cohort of 1455 pa-
tients from Cancer RNA-Seq Nexus was taken into account with 31 different breast
cancer subsets, 13 of which are invasive carcinomas at different stages. The subset
classification is built from observation of genotype and phenotype, and can for
instance refer to a specific type of stage of cancer, a disease state, or a particular
cell line. To assess differences in the metabolic response among the different types
and stages of breast cancer, we consider the average of RNA-Seq expression levels
within the same cancer subset, and we finally map these to the phenotypic space
of flux rates in the metabolic model using trilevel optimization (Figure 2, Figure
1 and File S2; see Methods for details on how phenotype predictions are achieved
from RNA-Seq data). GEMsplice correctly predicts breast cancer cells to grow
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Fig. 2. The 31 RNA-Seq profiles representing different breast cancer subsets
are mapped to the tridimensional space of biomass, pyruvate kinase and lac-
tate dehydrogenase. The trilevel linear program (1) is solved after constraining the
breast cancer metabolic model using each RNA-Seq expression profile from Cancer RNA-
Seq Nexus, including splice-isoform expression levels. The bottom left and both right
panels show the three projections onto each pair of axes. In each of these, the optimal
breast cancer profiles are highlighted and connected for both cancer and normal profiles
to identify the trade-off Pareto optimality.
faster than normal healthy cells, while keeping comparable levels of PK activity.
Some breast cancer cells are also predicted to use less PK compared to the healthy
counterpart, leading to accumulation of intermediates in the glycolytic pathway,
therefore fueling the serine biosynthesis pathway [28]. The trade-off between high
and low PK flux might also explain the balance between PKM2 (limiting step, con-
trolling PK flux) and PKM1 (promoting OXPHOS in the mitochondrion instead).
The trade-off between LDH and PK in cancer cells is also lower than in normal
cells in terms of negative flux rate values, consistent with the widely accepted ev-
idence that cancer cells use the reverse direction of LDH to produce lactate from
pyruvate (Warburg effect). When all the 31 breast cancer subsets are considered,
the bottom right panel shows a weak negative correlation between biomass and
negative flux of lactate dehydrogenase (Pearson’s r = −0.34, p-value = 7.60 ·10−2,
Spearman’s ρ = −0.37, p-value = 5.58 · 10−2). These predictions are in keeping
with the widely accepted fact that the amount of lactate production is positively
correlated with tumor growth. More specifically, in breast cancer, a positive corre-
lation has been highlighted between degree of malignancy, degree of mitochondrial
structural abnormality [29], and the most common biomarkers of malignant tumor,
e.g. intensive use of glycolysis and increased production of lactate [30].
Splice isoform expression-based flux control analysis
To further analyze the cancer-specific models, and to assess the role of the ex-
pression of splice isoforms in the model, we propose a steady-state control anal-
ysis based on transcript specificity. This method builds on the technique named
metabolic control analysis [31], which considers the relationship between enzyme
activity and flux rates. We adapt this analysis to assess the contribution of each
splice isoform to the cellular goals.
As described above, flux rates in our model also depend on the expression level of
splice isoforms. In each sample, a control analysis on flux rates vi with respect to
these expression levels xj involves the estimation of the relation between fractional
changes in the flux rates and fractional changes in the splice isoform expression.
This can be written as a scaled partial derivative of the form C = x
v
∂v
∂x
.
We here adopt an adjusted control coefficient by shrinking the sample-specific
denominator v towards its average v¯ across all the samples. As in the standard
deviation correction for differential expression tests [32], our correction prevents
gross overestimation of control coefficients. Without this correction, “false posi-
tives” would arise when vi(xj) is a very small value, irrespective of the numerator.
More formally, to approximate this partial derivative, we separately take into ac-
count each splice isoform j = 1, ..., N included in the breast cancer metabolic
model, and we evaluate positive and a negative intermediate control coefficients
C+ij and C
−
ij , defined as
C±ij =
vi(xj ± δ)− vi(xj)
(vi(xj) + v¯i)/2
/
δ
xj
, i = 1, ...,M, j = 1, ..., N, (3)
where δ is small enough so that the ratio approximates the derivative; vi is the
flux of interest (in our analysis, we focus on the three objectives of the linear
program, namely biomass, PK and LDH). Then, for each flux and splice isoform of
interest, we finally calculate the overall flux control coefficient Cij as the maximum
variation caused by a positive or negative perturbation of the isoform expression
level:
Cij = max(
∣∣C+ij ∣∣ , ∣∣C−ij ∣∣). (4)
These transcript- and cancer-specific coefficients evaluate the relative steady-state
change in three pivotal flux rates in breast cancer cells, with respect to the relative
change in the expression level of the transcript (see File S3). For our simulations,
we set the denominator xj = 1 to avoid proportionality between the final control
coefficient and the expression value itself, and δ = 10−3. In general, the smaller
the value chosen for δ, the more effective C in approximating the scaled derivative
of vi. Note that calculating a flux control coefficient for each splice isoform does
not explicitly identify controlling transcripts, but rather provides an effective way
to quantify their influence on the key flux rates in breast cancer cells.
The 10 most influential transcripts were selected independently for biomass, PK
and LDH. The union of these three sets of ten transcripts, composed of 14 tran-
scripts, was chosen to perform further enrichment analysis through PANTHER
[33]. A functional classification of each transcript was obtained using the “pro-
tein class” ontology, which is adapted from the PANTHER/X molecular function
ontology and also includes Gene Ontology (GO) annotations. Interestingly, the se-
lected transcripts are highly enriched for transmembrane transport and respiratory
electron transport chain.
As shown in Figure 3a, the most effective transcript at controlling the value of
biomass and LDH with a less stringent control on PK is ENST00000330775, a tran-
script of glucose-6-phosphate translocase (G6PT). In brain cancer, G6PT is a key
player in transducing intracellular signaling events; modulating its expression has
been proposed as an anti-cancer strategy [34]. Furthermore, our results suggest that
PK and LDH are maximally and simultaneously controlled by ENST00000591899
and ENST00000378667, transcripts of ubiquinol-cytochrome c reductase, whose
amplification was suggested to correlate with more aggressive breast cancer [35].
ENST00000507754 and ENST00000327772, transcripts of Complex I (whose activ-
ity is known to regulate breast cancer progression [36]), can control both PK and
LDH without disrupting the growth rate. Although further experimental investi-
gation is needed on these key transcripts, our genome-scale method may suggest
for the first time transcript-specific targets for anti-cancer strategies.
Pathway-based flux analysis
A pathway-based perspective has been often taken in genome-scale models with
the aim of investigating sensitivity analysis [37,38,39], and coupled with Bayesian
techniques to detect pathway crosstalks and temporal activation profiles [40]. To
assess the variation in the average flux of each pathway with respect to the un-
constrained breast cancer model, we here compute a normalized average pathway
flux
di =
(
w¯(i) − w(i)U
)
/w
(i)
U , i = 1, ..., P, (5)
where w¯(i) is the average flux in the ith pathway across the different cancer subsets,
while w
(i)
U indicates the flux of the ith pathway in the unconstrained breast cancer
model. To account for the tolerance of the linear solver, average pathway fluxes
of less than 10−10 were assumed to be zero. Pathways, defined using the KEGG
LIGAND database, were inherited from Recon1.
Figure 3b shows the indicator d plotted for each pathway when computed across
breast cancer cells and normal cells (results for invasive and unlabeled breast cells
are shown in Figure 2). The least-square linear regression reveals a positive pathway
flux correlation (Pearson’s r = 0.43, p-value = 1.82 · 10−3, Spearman’s ρ = 0.80,
p-value = 2.99 · 10−12). The eleven pathways indicated in the figure were detected
as outliers, with significantly different behavior between cancer and normal breast
cells.
To support our predictions, literature-based evidence of breast cancer alterations
in such pathways was aggregated. Alanine and aspartate are byproducts of amino
acid and glutamine fermentation, an important source for protein synthesis, espe-
cially when the cell lacks oxygen. Aspartate is also a main contributor to nucleotide
and protein synthesis; the malate/aspartate shuttle pathway translocates electrons
for the mitochondrial electron transport chain to produce ATP [41]. Perturbations
in the citric acid cycle (TCA) were largely expected because ot the known “War-
burg” reduction of glucose metabolism through the mitochondrion. Likewise, the
prediction of altered fatty acid elongation metabolism is in keeping with recent
studies reporting elongation of fatty acids as a marker in breast cancer [42].
GEMsplice also correctly predicts that pyrimidine biosynthesis pathways are down-
regulated in normal cells when compared to breast cancer cells [43]. Vitamin A and
carbohydrate altered metabolism are also associated with breast cancer [44,45]. In
breast cancer cells, Inosine monophosphate (IMP) dehydrogenase inhibitors cause
growth reduction and phenotypic alterations [46]. The prediction of starch and
sucrose metabolism confirms previous genome-wide association studies, which re-
ported significant relation between altered starch and sucrose pathway and the
risk of developing ER-negative breast cancer [47]. Sphingolipids are responsible
for oestrogen signaling and can control differentiation and proliferation of breast
cancer cells [48]. The glycerophospholipid pathway, also flagged as biomarker by
GEMsplice, was previously found altered in the metabolic phenotype of breast [49].
Finally, triacylglycerol was found to be a biomarker and a prognostic predictor of
poor clinical outcome in triple negative breast cancer [50].
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(a) (b) (c)
Fig. 3. Transcript-based metabolic flux and pathway analysis. (a) The control
analysis is applied to the set of 14 transcripts obtained as a union of the three sets
of ten most influential transcripts with respect to biomass, pyruvate kinase and lactate
dehydrogenase flux rate. Error bars represent the standard error of the mean SE = σ/
√
n,
where σ is the standard deviation of the measured effect, computed across all breast
cancer subsets, and n represents the number of breast cancer subsets. (b) The indicator
d plotted for each pathway in breast cancer versus normal breast cells (adjacent to tumor
cells). The size of each point represents the size of the corresponding pathway, quantified
as the number of reactions belonging to it. The y = x line is shown on the plots to
highlight outliers. By definition of d, if a pathway lies outside the line, its perturbation in
cancer samples is different from its perturbation in healthy samples. (Both perturbations
are computed with respect to the default breast cell model run without omic-derived
constraints.) Colors are given according to a normalized error of the computed mean
flux in each pathway, namely NE = σ/
√
p, where σ is the standard deviation of the
flux rate in the pathway, computed across all breast cancer subsets, and p represents
the size of the pathway. Note that the average flux in a pathway is positive or negative
depending on the direction in which its reactions take place. (c) GEMsplice correctly
predicts 13 out of 15 pathway increased/decreased activity (difference “Diff” between
upregulated and downregulated reactions), while GIMME only predicts 7 out of 15. More
accurate predictions are achieved for key cancer biomarkers: glycolysis, glycine, serine,
and threonine metabolism, and valine, leucine and isoleucine degradation.
Comparison with gene-level approaches
We here compare the results obtained by GEMsplice with GIMME [51], where ex-
pression levels are mapped to the model with gene-level resolution only. Present/absent
calls for GIMME were obtained by applying zFPKM normalization [52]. To com-
pare the pathway activity predicted by GEMsplice and GIMME in cancer condi-
tions, we computed the average absolute value of flux rates in all nonzero biomass
samples. As a benchmark for comparison and validation, we used the set of metabolic
pathways found to be significantly upregulated and downregulated in unfavorable
breast cancer conditions [53]. Pathways with equal number of upregulated and
downregulated reactions were excluded from the analysis.
GEMsplice correctly predicts 13 out of 15 pathway overexpression/underexpression
patterns, while GIMME only predicts 7 out of 15 (Figure 3c, and File S5). Three
key pathways widely accepted to be dysregulated in breast cancer are correctly
identified by GEMsplice, but incorrectly by GIMME: (i) glycolysis, highly up-
regulated in cancer, shows 3.44 cancer/normal fold change in GEMsplice, while
0.55 in GIMME; (ii) glycine, serine, and threonine metabolism, upregulated in
cancer: 2.54 fold change in GEMsplice, 0.41 in GIMME; (iii) valine, leucine and
isoleucine degradation, downregulated in cancer, 0.30 fold change in GEMsplice,
2.85 in GIMME.
The exact flux rates predicted for lactate dehydrogenase activity were also evalu-
ated against the widely-accepted cancer “Warburg” metabotype. Ten cancer sam-
ples are incorrectly predicted by GIMME with zero or negligible (< 10−12) “War-
burg” LDH flux (therefore not switching to aerobic glycolysis), while only three by
GEMsplice. Furthermore, all non-malignant and normal cells with nonzero growth
are correctly predicted by GEMsplice with lowest activity of LDH, while two out of
four nonzero-growth normal or non-malignant tissues are incorrectly predicted by
GIMME with a typical cancer metabotype, consisting of very high LDH activity.
These examples suggest that integrating splice isoform information with metabolic
models improves the characterization of breast cancer metabolism. With the cur-
rent fast-paced improvements in speed and costs of omic profiling, and therefore
with increasing availability of isoform-level model annotations and RNA-Seq data,
we expect such specific differences to increase even further.
4 Conclusion
While the rate of acquisition of omics data is rapidly increasing, analyzing and
extracting information through computational tools arguably remains the main
bottleneck in biology. Most studies focus on statistical analysis on gene expression
values to evaluate how they vary across different samples. However, modeling how
the gene expression alterations change metabolic processes at genome scale pro-
vides greater understanding of the phenotypic outcome with respect to studies in-
volving only transcriptomic data [54]. Given that the last decade in cancer research
has repeatedly shown that cancer is a complex disease that cannot be studied by
narrowing it down to a single gene or enzyme, a genome-wide metabolic approach
seems therefore the right direction to assess and predict the phenotype of a cancer
cell.
We here proposed GEMsplice, a method for linking gene expression and splice
isoform data to genome-scale metabolic models. GEMsplice is the first attempt at
solving one of the main issues of metabolic modeling: as outlined in recent reviews
[9,7,8,5], current methods only allow integration of omics data up to the gene level,
but not with splice-isoform resolution.
The idea is that every single profile can be used to create a profile-specific model
of metabolism that includes splice-isoform annotations. This integrated model can
be readily used to predict the flux rate of any biochemical reaction included in
the metabolic model, in a range of cancer subtypes. Individual profiles, patients
or cells related to the same cancer can be mapped onto this model, for instance
to cross-compare their metabolic behavior within the same cancer type, instead of
cross-comparing cells using transcriptomics data only.
Although it allows mapping cancer-specific transcript expression levels onto any
metabolic network, GEMsplice comes with limitations and room for improvement.
For instance, if reaction-specific information is available, the map from genes to
reaction flux bounds could be chosen in a reaction-specific manner and tailored to
specific environmental or growth conditions. Likewise, post-transcriptional regula-
tion of expression levels could be readily included in the model if available. On the
other hand, inconsistencies can be used to improve the model and the associated
biological knowledge on metabolic enzymes. For instance, incorrect predictions of
specific flux rates may shed light on where post-transcriptional regulation take
place [13]. A further development of cancer metabolic studies may involve a model
that takes into account interactions between cancer cells and their environment,
e.g. interactions with supporting cells. This approach will likely capture features
that cannot be observed with models of single cancer cells.
Breast cancer is manifested through a variety of effects that cannot be reduced
to a single feature. The difference in behavior of different cancer cells shows that
reconstructing a generic model of a cancer cell is not a viable approach [55]. Models
should therefore always be created in a tissue- and stage-specific fashion. We an-
ticipate that GEMsplice will allow for the first time the generation of such models
harnessing the full potential of RNA-Seq, and will facilitate in silico combinato-
rial experiments with RNA-Seq data. In fact, such omic-informed models can now
effectively integrate information on the expression level of splice isoforms, to date
largely ignored.
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Abstract. Motivation: Despite being often perceived as the main contributors
to cell fate and physiology, genes alone cannot predict cellular phenotype. During
the process of gene expression, 95% of human genes can code for multiple pro-
teins due to alternative splicing. While most splice variants of a gene carry the
same function, variants within some key genes can have remarkably different roles.
To bridge the gap between genotype and phenotype, condition- and tissue-specific
models of metabolism have been constructed. However, current metabolic models
only include information at the gene level. Consequently, as recently acknowledged
by the scientific community, common situations where changes in splice-isoform
expression levels alter the metabolic outcome cannot be modeled.
Results: We here propose GEMsplice, the first method for the incorporation of
splice-isoform expression data into genome-scale metabolic models. Using GEM-
splice, we make full use of RNA-Seq quantitative expression profiles to predict,
for the first time, the effects of splice isoform-level changes in the metabolism
of 1455 patients with 31 different breast cancer types. We validate GEMsplice
by generating cancer-versus-normal predictions on metabolic pathways, and by
comparing with gene-level approaches and available literature on pathways af-
fected by breast cancer. GEMsplice is freely available for academic use at https:
//github.com/GEMsplice/GEMsplice_code. Compared to state-of-the-art meth-
ods, we anticipate that GEMsplice will enable for the first time computational
analyses at transcript level with splice-isoform resolution.
Flux Balance Analysis (FBA)
To generate cancer-specific models from Cancer RNA-Seq Nexus, we propose an
extended flux balance analysis (FBA) framework. FBA has been successfully ap-
plied to predict growth rate and other metabolic observables in cells [1]. Starting
from the stoichiometry matrix S of all known metabolic reactions in a cell, and
given an unknown vector v of reaction flux rates, FBA models the steady-state
of a cell through the condition Sv = 0. Further constraints are added as a lower-
and upper-limit for the flux rate of each reaction. Through linear programming, a
combination of flux rates is chosen as an objective to be maximized or minimized.
The underdetermined linear system Sv = 0 is then solved and a distribution of flux
rates is determined according to the objectives chosen and the constraints added
on the flux rates. Standard FBA is extended through METRADE [2] to achieve
multi-omic integration and multi-level linear programming, as detailed in the main
manuscript.
GEMsplice pipeline
To build GEMsplice, we performed manual curation of the model using data as-
sociated with each gene in Recon1, retrieving transcript level information and all
available identifiers published as supplementary material but not included in the
model. We then mapped transcript identifiers in the Recon1 SBML file to tran-
script IDs used by databases, using BioMart [3] and Ensembl [4]. We finally used
these IDs within the breast cancer metabolic model by Jerby et al. [5]. Using a
RNA-Seq dataset and a method based on constraint-based programming, we were
able to map transcript expression levels, including splice isoforms, onto the breast
cancer model in order to generate 31 cancer-specific metabolic models. Cancer
RNA-Seq Nexus was used as a RNA-Seq dataset [6], including data from TCGA
[7], GEO [8] and SRA [9].
Analysis of invasive versus unlabeled cancer cells
Overall, unlabeled cancer cells, defined as the normal cells and the cells that have
not been clearly detected as invasive, are predicted to produce more biomass than
invasive cells. The trade-off frontiers in Figure 1 suggest that invasive cancer cells
outperform unlabeled cells in carrying a positive flux of pyruvate kinase while
ensuring a large flux for lactate dehydrogenase. More specifically, when compara-
ble flux rates of pyruvate kinase are considered, the invasive breast cancer cells
considered in our study are able to achieve a higher flux for the reverse reaction
lactate dehydrogenase, which in turn represents an increased Warburg effect, i.e.,
an increased production of lactate from pyruvate. This result supports the hypoth-
esis that aggressive phenotype and worse clinical outcome are positively correlated
with Warburg effect [10].
The pathways detected as outliers, with significantly different behavior between
invasive and unlabeled breast cell, are reported in Figure 2.The plot also shows
overall positive correlation between invasive and unlabeled perturbations (Pear-
son’s r = 0.22, p-value = 1.17 · 10−1, Spearman’s ρ = 0.63, p-value = 3.87 · 10−7).
This suggests that our method behaves consistently across different cancer sub-
sets, but also highlights pathways whose behavior is significantly changed in the
two cases.
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Fig. 1. The 31 RNA-Seq profiles representing different breast cancer subsets
are mapped to the tridimensional space of biomass, pyruvate kinase and lac-
tate dehydrogenase. The trilevel linear program (1) is solved after constraining the
breast cancer metabolic model using each RNA-Seq expression profile from the Cancer
RNA-Seq Nexus dataset, including splice-isoform expression levels. The bottom panels
show the three projections onto each pair of axes. In each of these two-dimensional objec-
tive spaces, the optimal breast cancer cells (in terms of trade-off Pareto optimality) are
found and connected by a line for invasive and unlabeled cells. Unlabeled cells are normal
cells or cells that have not been detected as invasive.
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Fig. 2. Transcript-based pathway analysis. Indicator d plotted for invasive breast
cancer versus unlabeled breast cells. The size of each point represent the number of
reactions in the pathway. Colors are given according to a normalized error of the computed
mean flux in each pathway, namely NE = σ/
√
p, where σ is the standard deviation of
the flux rate in the pathway, computed across all breast cancer subsets, and p represents
the size of the pathway. The y = x line is shown on the plots to highlight outliers. By
definition of d, if a pathway lies outside the line, its perturbation in cancer samples is
different from its perturbation in healthy samples (both perturbations are computed with
respect to the default breast cell model run without omic-derived constraints).
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